FDA Declares ZYN Pouches Less Harmful Than Cigarettes — But That's Not a Clean Bill of Health
The FDA has ruled that ZYN nicotine pouches carry lower risks than cigarettes for adults who switch completely. Here's what that really means.
FDA Grants ZYN a Modified Risk Label — With Major Strings Attached
The U.S. Food and Drug Administration has officially recognized certain ZYN nicotine pouches as a less harmful alternative to cigarettes — but public health experts are urging consumers not to interpret this as a stamp of safety.
The ruling grants Swedish Match, the company behind ZYN, a Modified Risk Tobacco Product (MRTP) designation for 20 specific products — 10 flavors across two nicotine strengths (3mg and 6mg). This designation allows the company to market those particular products as a lower-risk option, but only for adult smokers who completely abandon cigarettes in favor of the pouches.
To be clear: this is not FDA approval of nicotine pouches as a smoking cessation tool, and it is certainly not a declaration that they are safe.
A Market That Was Already Booming
The FDA's decision arrives long after nicotine pouches had already carved out a significant presence in the consumer market. Their appeal is easy to understand — they produce no smoke, no vapor, and can be used discreetly almost anywhere. Many users have come to view them as a "cleaner" way to consume nicotine.
That perception has translated into explosive growth. According to the World Health Organization, global retail sales of nicotine pouches reached 23.4 billion units in 2024, representing a surge of more than 50 percent compared to the prior year. Brands like ZYN, On!, and VELO have emerged as dominant players in the oral nicotine space, collectively reshaping how consumers think about nicotine alternatives.
In many respects, regulators are simply formalizing a cultural shift that consumers already set in motion.
The Broader Landscape of Nicotine Alternatives
The smoking alternatives market has evolved dramatically over the past decade. Traditional nicotine replacement therapies — patches, gum, and inhalers — remain FDA-approved tools specifically designed to help people quit smoking. However, they now exist alongside a rapidly expanding range of competing products.
Key Categories in the Market
- Oral nicotine pouches — Among the fastest-growing segments globally, led by ZYN, On!, and VELO.
- Vapes and disposable e-cigarettes — Still the dominant category in smoking alternatives, with U.S. market projections approaching $14.8 billion by 2030, despite persistent concerns about youth uptake.
- Heated tobacco devices — Products like IQOS heat tobacco rather than burning it, reducing exposure to many of the toxic byproducts associated with combustion.
Each of these categories carries its own risk profile, and none is without controversy.
What the FDA's Ruling Actually Says
The MRTP designation was issued after the FDA reviewed toxicology data, consumer behavior research, and public health modeling. The conclusion: adult smokers who fully transition to these specific ZYN products are likely exposing themselves to fewer harmful substances than those who continue smoking cigarettes.
Bret Koplow, acting director of the FDA's Center for Tobacco Products, stated that the ruling is designed to ensure "adult users have clear, science-based information about the relative harms of tobacco products, so they can make informed choices."
However, the ruling comes with two critical limitations:
- It applies only to 20 specific ZYN products — not to nicotine pouches as a category.
- The reduced-risk benefit applies exclusively to smokers who switch completely — those who continue using cigarettes or vapes alongside pouches do not receive the same benefit.
The FDA has also explicitly advised non-tobacco users to avoid nicotine pouches altogether.
Swedish Match is additionally required to monitor real-world usage patterns and submit ongoing reports to the FDA. The MRTP order carries a five-year validity period, subject to renewal or withdrawal.
The WHO Raises the Alarm
While the FDA has taken a cautiously permissive stance for a specific adult demographic, the World Health Organization has sounded a very different note. The WHO has flagged that nicotine pouches are gaining popularity among adolescents and young adults, citing their "strong youth appeal and high addiction potential."
The organization has also warned that regulation in many countries is struggling to keep pace with the category's rapid growth, and that brands are increasingly turning to social media influencers and youth-oriented marketing strategies to expand their reach.
The concern is straightforward: products that were originally positioned as harm-reduction tools for existing smokers could inadvertently create an entirely new generation of nicotine-dependent users.
The Bottom Line
The FDA's message is measured and deliberate. For adults who currently smoke and are looking for a lower-risk alternative, switching entirely to certain ZYN pouches may reduce their health risks. That is a meaningful distinction in public health terms.
But the agency is equally emphatic that no tobacco or nicotine product is truly safe, and that complete cessation of all nicotine use remains the single best path to improved health.
The question of who ultimately reaches for a nicotine pouch — a lifelong smoker looking for an exit ramp, or a young person who never smoked in the first place — is one that regulators, public health officials, and society at large will be grappling with for years to come.
